Audit 45606

FY End
2022-12-31
Total Expended
$268.62M
Findings
0
Programs
112
Year: 2022 Accepted: 2023-09-27

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
97.036 Covid-19 - Federal Emergency Management Agency Disaster Relief Fund $170.37M Yes 0
84.268 Federal Direct Student Loans-Hackensack Meridian School of Medicine $20.35M - 0
21.027 Covid-19 - Coronavirus State Fiscal Recovery Fund $14.66M Yes 0
93.855 Nih: Center to Develop Therapeutic Countermeasures to High-Threat Bacterial Agents $8.35M Yes 0
93.498 Covid-19 - Provider Relief Fund and American Rescue Plan (arp) Rural Distribution $5.93M Yes 0
93.855 Covid-19 - Metropolitan Antiviral Drug Accelerator $5.62M Yes 0
93.323 Covid-19 - Sars-Cov-2 Hospital Testing 2021 $3.29M - 0
84.181 Services: Early Intervention System, Special Education Grants for Infants and Families $2.78M - 0
93.378 Integrated Care for Kids Model $2.53M - 0
84.268 Federal Direct Student Loans $2.33M - 0
93.855 Nih: Novel Bi-Specific Immunoprophylactics Against Multi-Drug Resistant Gram-Negative Bacterial Infections $2.24M Yes 0
93.855 Novel Bi-Specific Immunotherapeutic Against High-Threat Gram-Negative Pathogens $1.54M Yes 0
93.855 Harnessing B Cells for Tb Vaccine Development to Improve Therapy of Tb and Tb-Hiv Coinfection $1.44M Yes 0
93.461 Covid-19 - Hrsa Covid-19 Claims Reimbursement for the Uninsured Program and the Covid-19 Coverage Assistance Fund $1.16M Yes 0
93.855 A Dual-Beta-Lactam Strategy for Treating Multidrug Resistant M Abscessus $1.05M Yes 0
93.865 Epigenetics of Down Syndrome $1.03M Yes 0
93.855 Immunometabolic Regulations of Pulmonary Tb Pathogenesis by Adipose Tissue $992,477 Yes 0
16.575 New Jersey Hospital-Based Violence Intervention Program $919,987 - 0
93.839 Dot1l, Reconstitution of Plasmacytoid Dendritic Cells and Alloimmunity $893,861 Yes 0
93.855 Determinants of Tb Control, Relapse and Reinfection $848,165 Yes 0
93.493 Community Project Funding/congressionally Directed Spending Construction $775,000 - 0
93.855 Transmission Aerobiology of M. Tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across An Evolutionary Bottleneck $770,607 Yes 0
12.420 Reinnervation of Paralyzed Limb Muscle by Nerve-Muscle-Endplate Grafting Technique $749,082 Yes 0
93.855 Translational Approaches to Improve Understanding and Outcome in Tuberculous Meningitis $728,970 Yes 0
93.855 Nih: Target Based Discovery of Next Generation Pyrazinamide $693,625 Yes 0
93.866 Rejuvenation of Aged Hematopoietic Stem Cells and Endothelial Niches by Thrombospondin -1 Blockade $675,571 Yes 0
93.855 Combatting Natural Resistance and Persistence in Non-Tb Mycobacterial Disease $562,069 Yes 0
93.855 Ezh2 Regulates Follicular Helper T Cell Differentiation $490,155 Yes 0
93.855 Nih: Critical Factors Influencing Echinocandin Resistance in Candida Glabrata $488,113 Yes 0
93.855 Tcf1 Programs Cd8 T Cell Responses to Enhance Viral and Cancer Immunity $480,594 Yes 0
93.855 Synthetic Rescue of Antigen-Driven T Cells and Alloimmunity $408,784 Yes 0
12.420 Covid-19 - Phase II Randomized Study of Convalescent Plasma As Treatment for Subjects with Early Covid-19 Infection $397,735 Yes 0
93.396 Harnessing the Thymus for Long-Term Tumor Control with Hematopoietic Stem Cell-Derived Naive Car T Cells $374,500 Yes 0
93.650 Hackensack University Medical Center Accountable Health Communities Track 2 Assistance Intervention:improving Population Health in Bergen County, New Jersey $362,397 Yes 0
93.247 Ane- Nurse Practitioner Residency Program $351,384 - 0
84.063 Federal Pell Grant Program $342,189 - 0
16.575 Community-Based Violence Intervention Program $284,365 - 0
93.855 Nih: the Molecular Basis of the Carbapenem Resistance Epidemic $283,141 Yes 0
93.838 Exhaled Small Rna Biomarkers to Detect and Monitor Airway Disease $262,221 Yes 0
93.917 Hiv/aids Ryan White Part B Application 2022 $256,235 - 0
93.433 Nidilrr Disability and Rehab. Research Projects Tbi Model Systems $252,694 Yes 0
93.398 Leveraging Behavioral Science to Improve Patient Understanding of Advanced Cancer $236,310 Yes 0
93.855 Novel Strategies for Antibiotic Combinations to Combat Gram-Negative Superbugs $216,534 Yes 0
93.397 Epigenetic Therapies - New Approaches, Project 1 $206,221 Yes 0
93.914 Ryan White - March 1, 2022 - December 31, 2022 $204,457 - 0
12.420 Biomarkers and Pathogenesis of Cutaneous Fibrosis $198,419 Yes 0
93.395 Targeting Transcriptional CO-Repressor Corest Complex in Melanoma $198,005 Yes 0
93.855 Nih: Siderophore Inhibitors for Tuberculosis That Block Mycobactin Biosynthesis $186,908 Yes 0
93.855 Nih: Targeting Biotin Metabolism in Mycobacterium Tuberculosis $183,820 Yes 0
93.855 C5a/c5ar1 Signaling in Protective Immunity During Invasive Candidiasis $177,455 Yes 0
16.045 Project Heal: Expansion of Community-Based Violence Intervention & Prevention Initiatives $173,085 - 0
93.394 Molecular Markers of Risk of Subsequent Invasive Breast Cancer in Women with Ductal Carcinoma in Situ $170,165 Yes 0
97.067 Urban Area Security Initiative $149,999 - 0
93.113 Dna Repair Phenotype the Missing Link in Breast Cancer Risk Assessment $148,339 Yes 0
93.398 Elucidating the Role of Smad4 in Colorectal Cancer $137,385 Yes 0
93.889 Covid-19 - Philep Emergency Funding 2021 $131,555 - 0
93.393 Tmem, Menacalc, and Menainv As Prognostic and Predictive Markers for Breast Cancer Metastasis $130,986 Yes 0
93.243 Icare Integrated Care for Addiction Recovery Expansion $127,869 - 0
93.398 Experimental Evolution of Pancreatic Cancer $127,200 Yes 0
93.855 A Preclinical Program for Targeting Mycobacterium Tuberculosis Kasa $123,874 Yes 0
93.914 Ryan White $120,990 - 0
93.855 Hx Nih Ctcf in Cd8 Tcell $119,736 Yes 0
93.866 Mtor Dependent Regulation of Hematopoietic Stem Cell Aging and Longevity $112,239 Yes 0
93.243 Hmh Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (aide) $111,769 - 0
93.153 Pediatric Aids 2022 $111,667 - 0
93.870 New Jersey Home Visiting Initiative: Parents As Teachers $110,653 - 0
93.853 Targeting Lewy Body Specific Pathology Using Biomarkers $104,674 Yes 0
93.226 Simulation to Improve Infection Prevention and Patient Safety: the Sipps Trial $103,210 Yes 0
93.855 Polyclonality of Carbapenem Resistant Enterobacteriaceae Bloodstream Infections $99,319 Yes 0
93.917 Hiv/aids Ryan White Part B Application 2021 $98,826 - 0
93.847 Leptin Reduction As A Potent Mitigative Strategy for the Treatment of Pasc $98,066 Yes 0
12.420 Role of Core-Binding Factor Rearrangements in Triple-Negative Breast Cancer Progression and Immune Evasion $95,731 Yes 0
93.855 Restoring Beta-Lactam Efficacy Against Methciillin-Resistant Staphylococci $88,550 Yes 0
93.310 Covid-19 Network of Networks Expanding Clinical and Translational Approaches to Predict Severe Illness in Children $60,000 Yes 0
84.425 Covid-19 - Cares Act: Higher Education Emergency Relief Funds $57,928 - 0
93.395 A Reciprocal Support Writing Intervention to Reduce Symptoms During Stem Cell Transplant Study $54,898 Yes 0
93.994 Child Evaluation Center $54,000 - 0
12.420 Dod: Chemigenomic Drug Discovery for Tuberculosis $51,851 Yes 0
93.310 Development Impact of Nicu Exposures (dine) $40,648 Yes 0
93.914 Ryan White - January 1, 2022 - February 28, 2022 $37,715 - 0
84.007 Federal Supplemental Education Opportunity Grant Program $33,100 - 0
12.420 Pinpointing Functional Noncoding Mutations in Ccrcc $32,097 Yes 0
93.855 Antibacterial Resistance Leadership Group (arlg) $30,695 Yes 0
93.940 Ending the Epidemic: to Perform Enhanced Hiv Services $30,000 Yes 0
93.855 Lesion-Centric Optimization of Multidrug Therapies for Tuberculosis $29,785 Yes 0
93.855 Antibiotic Resistance Among Hypermutator Carbapenem Resistant Klebsiella Pneumoniae $28,517 Yes 0
93.994 Special Child Health Child Evaluation Centers 2023 $26,939 - 0
93.110 New Jersey Family-Centered Mental Health Access Program Telehealth $25,897 - 0
93.838 Covid-19 - Clock Consortium for Pasc Phase II Recover Pediatric Cohort $25,104 Yes 0
93.855 Elucidating Mediators of Genetic Instability in Candida Glabrata $23,208 Yes 0
93.153 Pediatric Aids 2023 $22,755 - 0
93.994 Special Child Health Child Evaluation Centers 2022 $21,984 - 0
97.025 Spf2022-0068pwusar Ian Depl $21,812 - 0
93.397 Epigenetic Therapies - New Approaches, Pathology Core $21,657 Yes 0
93.924 Ryan White Hiv/aids Dental Reimbursement $17,997 - 0
93.855 Modulating Costimulation Pathways to Improve Follicular Helper T Cell and Antibody Responses $17,809 Yes 0
93.853 Comparing Treatment Approaches to Promote Inpatient Rehabilitation Effectiveness for Traumatic Brain Injury (care 4 Tbi) $17,417 Yes 0
93.393 Home-Based Virtual Reality System for the Treatment of Chemotherapy-Related Cognitive Impairments $16,300 Yes 0
93.397 Georgetown University Lombardi Comprehensive Cancer Center Support Grant $15,770 Yes 0
93.866 Telerehabilitation Combining Virtual Reality Adaptable Games and Drug Therapy for Early Alzheimers Disease $15,462 Yes 0
93.855 Defining Stim1 Function at the Immunological Synapse $15,436 Yes 0
93.855 Using Collaborative Cross Mice to Develop A Novel Model of Mycobacterium Abscesses Lung Infection" $11,012 Yes 0
93.865 The Patient Journey for Children with Medical Complexity During the Pandemic Era and Its Implications $9,757 Yes 0
93.393 Bridging Information Divides and Gaps to Ensure Survivorship $9,754 Yes 0
93.433 Characterization and Treatment of Chronic Pain After Severe Traumatic Brain Injury $9,000 Yes 0
93.393 Empathic Communication Skills Training to Reduce Lung Cancer Stigma $6,054 Yes 0
93.110 Severe Combined Immunodeficiency (scid) Screening and Education $6,000 - 0
93.855 Identifying Drug-Resistant Can $5,460 Yes 0
93.393 Multilevel Interventions to Increase Adherence to Lung Cancer Screening $5,115 Yes 0
93.361 Patients Perceptions of Electronic Health Record Use During Initial Oncology Outpatient Clinic Visits $4,737 Yes 0
93.914 Covid-19 - Ryan White $1,500 - 0
93.855 Bacterial Characteristics of Community-Associated Carbepenem-Resistant Enterobacteriaceae $1,169 Yes 0

Contacts

Name Title Type
LV8GL8MLU9A3 Christopher Little Auditee
6095291968 Tim Weld Auditor
No contacts on file

Notes to SEFA

Title: Pass-through Awards Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the Federal Schedule) presentsthe activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. andits subsidiaries (the Network) that have been financed by the U.S. Government.The information in this Federal Schedule is presented in accordance with the requirements of theTitle 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, CostPrinciples, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, someamounts presented in this Federal Schedule may differ from amounts presented in or used inpreparation of the consolidated financial statements. All financial assistance received directly fromfederal agencies, as well as financial assistance passed through other governmental agencies ornonprofit organizations, are included on the Federal Schedule. Direct and indirect costs arecharged to awards in accordance with cost principles contained in the Department of Health andHuman Services (DHHS), U.S. Office of the Assistant Secretary Comptroller (OASC), OASC-3,A Guide for Hospitals. Under these cost principles, certain types of expenditures are not allowableor are limited as to reimbursement. The accompanying Federal Schedule is presented on theaccrual basis of accounting. Because the Federal Schedule presents only a selected portion of theactivities of the Network, it is not intended to, and does not, present the consolidated financialposition, results of operations, and changes in net assets or cash flows of the Network.The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. TheNetwork charges indirect costs to federal awards based on award-specific rates as defined in eachgrant award. While certain awards on the Federal Schedule have program names identified asaward year 2023, only expenses incurred during the year ended December 31, 2022 are reportedon the Federal Schedule. These awards have grant periods that do not align with the Networkscalendar year end. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. Full Assistance Listing Numbers (ALN) and pass through award numbers are presented where available and applicable.
Title: Federal Direct Student Loan Program Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the Federal Schedule) presentsthe activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. andits subsidiaries (the Network) that have been financed by the U.S. Government.The information in this Federal Schedule is presented in accordance with the requirements of theTitle 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, CostPrinciples, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, someamounts presented in this Federal Schedule may differ from amounts presented in or used inpreparation of the consolidated financial statements. All financial assistance received directly fromfederal agencies, as well as financial assistance passed through other governmental agencies ornonprofit organizations, are included on the Federal Schedule. Direct and indirect costs arecharged to awards in accordance with cost principles contained in the Department of Health andHuman Services (DHHS), U.S. Office of the Assistant Secretary Comptroller (OASC), OASC-3,A Guide for Hospitals. Under these cost principles, certain types of expenditures are not allowableor are limited as to reimbursement. The accompanying Federal Schedule is presented on theaccrual basis of accounting. Because the Federal Schedule presents only a selected portion of theactivities of the Network, it is not intended to, and does not, present the consolidated financialposition, results of operations, and changes in net assets or cash flows of the Network.The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. TheNetwork charges indirect costs to federal awards based on award-specific rates as defined in eachgrant award. While certain awards on the Federal Schedule have program names identified asaward year 2023, only expenses incurred during the year ended December 31, 2022 are reportedon the Federal Schedule. These awards have grant periods that do not align with the Networkscalendar year end. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. The Network is responsible only for the performance of certain administrative duties with respect to the Federal Direct Student Loan Program and, accordingly, the total outstanding loans are not included in the Networks consolidated financial statements. It is not practical to determine thebalance of loans outstanding to students under this program as of December 31, 2022. The schedule of expenditures of federal awards includes loans granted in 2022.
Title: COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured Program and Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the Federal Schedule) presentsthe activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. andits subsidiaries (the Network) that have been financed by the U.S. Government.The information in this Federal Schedule is presented in accordance with the requirements of theTitle 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, CostPrinciples, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, someamounts presented in this Federal Schedule may differ from amounts presented in or used inpreparation of the consolidated financial statements. All financial assistance received directly fromfederal agencies, as well as financial assistance passed through other governmental agencies ornonprofit organizations, are included on the Federal Schedule. Direct and indirect costs arecharged to awards in accordance with cost principles contained in the Department of Health andHuman Services (DHHS), U.S. Office of the Assistant Secretary Comptroller (OASC), OASC-3,A Guide for Hospitals. Under these cost principles, certain types of expenditures are not allowableor are limited as to reimbursement. The accompanying Federal Schedule is presented on theaccrual basis of accounting. Because the Federal Schedule presents only a selected portion of theactivities of the Network, it is not intended to, and does not, present the consolidated financialposition, results of operations, and changes in net assets or cash flows of the Network.The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. TheNetwork charges indirect costs to federal awards based on award-specific rates as defined in eachgrant award. While certain awards on the Federal Schedule have program names identified asaward year 2023, only expenses incurred during the year ended December 31, 2022 are reportedon the Federal Schedule. These awards have grant periods that do not align with the Networkscalendar year end. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. The Network conducted COVID-19 testing and/or provided treatment for uninsured individuals with a COVID-19 primary diagnosis on or after February 4, 2020 and as such has requested claims reimbursement under DHHS ALN 93.461 Health Resources and Services Administrations (HRSA) COVID-19 Claims Reimbursement for the Uninsured Program and the COVID-19 Coverage Assistance Fund. The Network has recorded $1,164 on the Federal Schedule from DHHS on claims with service dates during fiscal year 2022 which were fully reimbursed as ofDecember 31, 2022 (claims for testing and treatment were accepted through March 22, 2022 and claims for vaccine administration were accepted through April 5, 2022).
Title: COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distri Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the Federal Schedule) presentsthe activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. andits subsidiaries (the Network) that have been financed by the U.S. Government.The information in this Federal Schedule is presented in accordance with the requirements of theTitle 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, CostPrinciples, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, someamounts presented in this Federal Schedule may differ from amounts presented in or used inpreparation of the consolidated financial statements. All financial assistance received directly fromfederal agencies, as well as financial assistance passed through other governmental agencies ornonprofit organizations, are included on the Federal Schedule. Direct and indirect costs arecharged to awards in accordance with cost principles contained in the Department of Health andHuman Services (DHHS), U.S. Office of the Assistant Secretary Comptroller (OASC), OASC-3,A Guide for Hospitals. Under these cost principles, certain types of expenditures are not allowableor are limited as to reimbursement. The accompanying Federal Schedule is presented on theaccrual basis of accounting. Because the Federal Schedule presents only a selected portion of theactivities of the Network, it is not intended to, and does not, present the consolidated financialposition, results of operations, and changes in net assets or cash flows of the Network.The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. TheNetwork charges indirect costs to federal awards based on award-specific rates as defined in eachgrant award. While certain awards on the Federal Schedule have program names identified asaward year 2023, only expenses incurred during the year ended December 31, 2022 are reportedon the Federal Schedule. These awards have grant periods that do not align with the Networkscalendar year end. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. The Federal Schedule includes grant activity related to the DHHS Coronavirus Aid Relief and Economic Security (CARES) Act ALN 93.498 Provider Relief Fund (PRF). The PRF is administered by HRSA. As required based on guidance in the 2022 OMB Compliance Supplement, the Federal Schedule includes all Period 3 funds received between January 1, 2021 and June 30, 2021 and expended by June 30, 2022 and all Period 4 funds received between July 1, 2021 to December 31, 2021 and expended by December 31, 2022 as reported to HRSA via the PRF Reporting Portal. The Federal Schedule, thus, includes $5,927 of lost revenue. Pursuant to the guidance provided by DHHS, the Network will include all PRF funds received between January 1, 2022 and December 31, 2022 (Periods 5 and 6) on its Federal Schedule for the year ending December 31, 2023.
Title: COVID-19 Federal Emergency Management Agency Disaster Relief Fund (FEMA Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the Federal Schedule) presentsthe activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. andits subsidiaries (the Network) that have been financed by the U.S. Government.The information in this Federal Schedule is presented in accordance with the requirements of theTitle 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, CostPrinciples, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, someamounts presented in this Federal Schedule may differ from amounts presented in or used inpreparation of the consolidated financial statements. All financial assistance received directly fromfederal agencies, as well as financial assistance passed through other governmental agencies ornonprofit organizations, are included on the Federal Schedule. Direct and indirect costs arecharged to awards in accordance with cost principles contained in the Department of Health andHuman Services (DHHS), U.S. Office of the Assistant Secretary Comptroller (OASC), OASC-3,A Guide for Hospitals. Under these cost principles, certain types of expenditures are not allowableor are limited as to reimbursement. The accompanying Federal Schedule is presented on theaccrual basis of accounting. Because the Federal Schedule presents only a selected portion of theactivities of the Network, it is not intended to, and does not, present the consolidated financialposition, results of operations, and changes in net assets or cash flows of the Network.The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. TheNetwork charges indirect costs to federal awards based on award-specific rates as defined in eachgrant award. While certain awards on the Federal Schedule have program names identified asaward year 2023, only expenses incurred during the year ended December 31, 2022 are reportedon the Federal Schedule. These awards have grant periods that do not align with the Networkscalendar year end. De Minimis Rate Used: N Rate Explanation: The auditee did not use the de minimis cost rate. As of December 31, 2022, the Network recorded $170,366 of claims to FEMA under ALN 97.036. The claims submitted represented incurred eligible capital and operating expenses attributed to the Networks response to COVID-19 which were not only expended but also obligated by the federal and state agencies. The Network has additional claims outstanding and under review with FEMA as of December 31, 2022 which will be recognized in the year the related funds are obligated by the federal and state agencies.